Enfortumab vedotin (EV) in triple-negative breast cancer (TNBC) and HR+/HER2-breast cancer (BC) cohorts of EV-202 Meeting Abstract
| Authors: | Giordano, A.; Awan, A. A. A.; Bruce, J. Y.; Rugo, H. S.; Diamond, J. R.; Novik, Y.; Baranda, J. C.; Muro, K.; Ono, M.; Nanda, R.; Kaplan, J.; Gorla, S. R.; Liu, S.; Wozniak, M.; Lee, A.; Traina, T. A. |
| Abstract Title: | Enfortumab vedotin (EV) in triple-negative breast cancer (TNBC) and HR+/HER2-breast cancer (BC) cohorts of EV-202 |
| Meeting Title: | 2024 ASCO Annual Meeting |
| Journal Title: | Journal of Clinical Oncology |
| Volume: | 42 |
| Issue: | 16 Suppl. |
| Meeting Dates: | 2024 May 31-Jun 4 |
| Meeting Location: | Chicago, IL |
| ISSN: | 0732-183X |
| Publisher: | American Society of Clinical Oncology |
| Date Published: | 2024-06-01 |
| Language: | English |
| ACCESSION: | WOS:001275557400115 |
| PROVIDER: | wos |
| DOI: | 10.1200/JCO.2024.42.16_suppl.1005 |
| Notes: | Meeting Abstract: 1005 -- Source: Wos |
